Pharmaceutical and Life Sciences Deals Insights Quarterly

February 2015
  • Print-friendly version
Pharmaceutical and Life Sciences Deals Insights Quarterly

At a glance

Deal activity remained strong from the prior quarter as there was over $105 billion in announced and pending deals suggesting robust M&A activity may continue into 2015. As companies complete deals, integration becomes critical to achieving synergies. In this publication, we explore some of the methods being used to maximize synergies in the R&D function. Additionally this quarter's report's market spotlight looks at how Canada is essential to the development of future IP for companies within the industry. Canada has focused on becoming one of the most cost-effective countries for clinical development among the Group of Seven (G7) industrialized nations.

Further reading:

US Pharmaceuticals and Life Sciences Deals Insights Quarterly Q3 2014

US Pharmaceuticals and Life Sciences Deals Insights Quarterly Q2 2014

US Pharmaceuticals and Life Sciences Deals Insights Quarterly Q1 2014

US Pharmaceuticals and Life Sciences Deals Insights Quarterly Q4 2013

US Pharmaceuticals and Life Sciences Deals Insights Quarterly Q3 2013

US Pharmaceuticals and Life Sciences Deals Insights Quarterly Q2 2013